文献速递白血病

新辅助Talazoparib治疗可手术gBRCA阳性乳腺癌

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
PubMed 文献 · J Clin Oncol · 2019-08-28

本研究评估单药Talazoparib口服6个月对gBRCA阳性可手术乳腺癌的病理反应。20例患者中RCB-0率为53%,RCB-0/I为63%,毒性可管理。单药Talazoparib的实质病理反应支持更大规模新辅助试验。

要点

  • gBRCA阳性可手术乳腺癌单药Talazoparib 6个月,RCB-0率53%,RCB-0/I率63%。
  • 8例(40%)发生3级贫血需输血,9例需减量,毒性可管理。
  • 单药Talazoparib的病理反应支持正在进行的更大规模新辅助试验。

核心结论

  • 新辅助单药口服Talazoparib每日一次6个月不联合化疗产生了实质性的RCB-0率,毒性可管理。
  • 单药Talazoparib的实质性病理反应支持更大规模、正在进行的新辅助试验(NCT03499353)。

研究设计与样本

  • 研究纳入1 cm或以上浸润性肿瘤且gBRCA阳性的可手术乳腺癌患者,排除HER2阳性肿瘤。
  • 20例患者接受预处理活检,随后口服Talazoparib 1 mg每日一次6个月,之后接受根治性手术;辅助治疗由医生决定。
  • 主要终点为残余癌症负荷(RCB);20例患者中RCB-0加RCB-I缓解率的95%CI半宽小于20%。
  • 2016年8月至2017年9月入组20例患者,中位年龄38岁(范围23至58岁);16例gBRCA1阳性,4例gBRCA2阳性。

主要发现

  • 1例患者选择术前化疗,未纳入RCB分析。
  • RCB-0(病理完全缓解)率为53%,RCB-0/I率为63%。
  • 8例(40%)发生3级贫血需输血,3例发生3级中性粒细胞减少,1例发生4级血小板减少。
  • 常见1或2级毒性为恶心、疲乏、中性粒细胞减少、脱发、头晕和呼吸困难;毒性通过减量和输血管理。
  • 9例需要减量。

临床怎么用

  • gBRCA阳性可手术乳腺癌患者可考虑新辅助单药口服Talazoparib 1 mg每日一次6个月,不联合化疗。
  • 治疗期间需监测贫血、中性粒细胞减少和血小板减少,必要时减量或输血支持。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer. METHODS: Eligibility included 1 cm or larger invasive tumor and gBRCA-positive disease. Human epidermal growth factor receptor 2-positive tumors were excluded. Twenty patients underwent a pretreatment biopsy, 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery. Patients received adjuvant therapy at physician's discretion. The primary end point was residual cancer burden (RCB). With 20 patients, the RCB-0 plus RCB-I response rate can be estimated with a 95% CI with half width less than 20%. RESULTS: Twenty patients were enrolled from August 2016 to September 2017. Median age was 38 years (range, 23 to 58 years); 16 patients were gBRCA1 positive and 4 patients were gBRCA2 positive. Fifteen patients had triple-negative breast cancer (estrogen receptor/progesterone receptor < 10%), and five had hormone receptor-positive disease. Five patients had clinical stage I disease, 12 had stage II, and three had stage III, including one patient with inflammatory breast carcinoma and one with metaplastic chondrosarcomatous carcinoma. One patient chose to receive chemotherapy before surgery and was not included in RCB analyses. RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%. Eight patients (40%) had grade 3 anemia and required a transfusion, three patients had grade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia. Common grade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea. Toxicities were managed by dose reduction and transfusions. Nine patients required dose reduction. CONCLUSION: Neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy produced substantial RCB-0 rate with manageable toxicity. The substantive pathologic response to single-agent talazoparib supports the larger, ongoing neoadjuvant trial (ClinicalTrials.gov identifier: NCT03499353).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2019. PMID: 31461380. doi:10.1200/JCO.19.01304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。